通过聚乙二醇连接改变小鼠体内牛腺苷脱氨酶的循环寿命和抗原特性。
Alteration of the circulating life and antigenic properties of bovine adenosine deaminase in mice by attachment of polyethylene glycol.
作者信息
Davis S, Abuchowski A, Park Y K, Davis F F
出版信息
Clin Exp Immunol. 1981 Dec;46(3):649-52.
Abstract
Polyethylene glycol was attached covalently to adenosine deaminase (ADA) using cyanuric chloride as the coupling agent. The modified adenosine deaminase (PEG-ADA) appears to lose its immunogenicity in mice following multiple intravenous injections. PEG-ADA does not react with antibodies raised against native ADA. The circulating half-life (T1/2) of PEG-ADA was increased to 28 hr. The lack of detectable antibody formation and long circulating life may make PEG-ADA suitable for treating human ADA deficiency.
摘要
以三聚氯氰作为偶联剂，将聚乙二醇共价连接到腺苷脱氨酶（ADA）上。多次静脉注射后，修饰后的腺苷脱氨酶（PEG-ADA）在小鼠体内似乎失去了免疫原性。PEG-ADA不与针对天然ADA产生的抗体发生反应。PEG-ADA的循环半衰期（T1/2）延长至28小时。无法检测到抗体形成以及循环寿命延长，这可能使PEG-ADA适用于治疗人类ADA缺乏症。
相似文献
1
Alteration of the circulating life and antigenic properties of bovine adenosine deaminase in mice by attachment of polyethylene glycol.
Clin Exp Immunol. 1981 Dec;46(3):649-52.
2
IgG antibody response to polyethylene glycol-modified adenosine deaminase in patients with adenosine deaminase deficiency.
J Clin Invest. 1992 May;89(5):1643-51. doi: 10.1172/JCI115761.
3
4
Murine monoclonal antibodies which recognize adenosine deaminase from calf, mouse, rat and man.
Immunol Lett. 1985;10(3-4):145-9. doi: 10.1016/0165-2478(85)90069-0.
5
Enzyme replacement therapy with polyethylene glycol-adenosine deaminase in adenosine deaminase deficiency: overview and case reports of three patients, including two now receiving gene therapy.
Pediatr Res. 1993 Jan;33(1 Suppl):S42-7; discussion S47-8. doi: 10.1203/00006450-199305001-00236.
6
Preparation of a non-immunogenic arginase by the covalent attachment of polyethylene glycol.
Biochim Biophys Acta. 1979 May 23;578(1):47-53. doi: 10.1016/0005-2795(79)90111-9.
7
Adenosine deaminase deficiency with late onset of recurrent infections: response to treatment with polyethylene glycol-modified adenosine deaminase.
J Pediatr. 1988 Aug;113(2):312-7. doi: 10.1016/s0022-3476(88)80271-3.
8
Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol.
J Biol Chem. 1977 Jun 10;252(11):3578-81.
9
In vitro and in vivo studies with human carrier erythrocytes loaded with polyethylene glycol-conjugated and native adenosine deaminase.
Br J Haematol. 2000 Jun;109(3):549-54. doi: 10.1046/j.1365-2141.2000.02059.x.
10
[Treatment of adenosine deaminase deficiency with adenosine deaminase combined with polyethylene glycol].
Arch Fr Pediatr. 1992 Apr;49(4):339-43.
引用本文的文献
1
Strategies to Enhance Protein Delivery.
Langmuir. 2025 Mar 18;41(10):6457-6470. doi: 10.1021/acs.langmuir.4c04636. Epub 2025 Mar 7.
2
Polymer-prodrug conjugates as candidates for degradable, long-acting implants, releasing the water-soluble nucleoside reverse-transcriptase inhibitor emtricitabine.
J Mater Chem B. 2023 Dec 13;11(48):11532-11543. doi: 10.1039/d3tb02268d.
3
Monocytic MDSCs exhibit superior immune suppression via adenosine and depletion of adenosine improves efficacy of immunotherapy.
Sci Adv. 2023 Jun 30;9(26):eadg3736. doi: 10.1126/sciadv.adg3736.
4
A Review of Protein- and Peptide-Based Chemical Conjugates: Past, Present, and Future.
Pharmaceutics. 2023 Feb 10;15(2):600. doi: 10.3390/pharmaceutics15020600.
5
Purification of Modified Therapeutic Proteins Available on the Market: An Analysis of Chromatography-Based Strategies.
Front Bioeng Biotechnol. 2021 Aug 20;9:717326. doi: 10.3389/fbioe.2021.717326. eCollection 2021.
6
Adenosine Deaminase 1 Overexpression Enhances the Antitumor Efficacy of Chimeric Antigen Receptor-Engineered T Cells.
Hum Gene Ther. 2022 Mar;33(5-6):223-236. doi: 10.1089/hum.2021.050. Epub 2021 Aug 25.
7
Comparison of elapegademase and pegademase in ADA-deficient patients and mice.
Clin Exp Immunol. 2020 May;200(2):176-184. doi: 10.1111/cei.13420. Epub 2020 Feb 9.
8
Early Enzyme Replacement Therapy Improves Hearing and Immune Defects in Adenosine Deaminase Deficient-Mice.
Front Immunol. 2019 Mar 13;10:416. doi: 10.3389/fimmu.2019.00416. eCollection 2019.
9
Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities.
Nanomedicine (Lond). 2019 Jan;14(1):93-126. doi: 10.2217/nnm-2018-0120. Epub 2018 Nov 19.
10
Enzymes as Immunotherapeutics.
Bioconjug Chem. 2018 Mar 21;29(3):649-656. doi: 10.1021/acs.bioconjchem.7b00719. Epub 2018 Jan 31.
本文引用的文献
1
Determination of free amino groups in proteins by trinitrobenzenesulfonic acid.
Anal Biochem. 1966 Mar;14(3):328-36. doi: 10.1016/0003-2697(66)90275-2.
2
Combined immunodeficiency disease associated with adenosine deaminase deficiency. Report on a workshop held in Albany, New York, October 1, 1973.
J Pediatr. 1975 Feb;86(2):169-81. doi: 10.1016/s0022-3476(75)80463-x.
3
Enzyme replacement therapy for adenosine deaminase deficiency and severe combined immunodeficiency.
N Engl J Med. 1976 Dec 9;295(24):1337-43. doi: 10.1056/NEJM197612092952402.
4
Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol.
J Biol Chem. 1977 Jun 10;252(11):3578-81.
5
Reconstitution of B and T lymphocyte function in severe combined immunodeficiency disease after transplantation with thymic epithelium.
Lancet. 1976 Dec 11;2(7998):1270-2. doi: 10.1016/s0140-6736(76)92031-6.
Zotero 插件